ION337 for epilepsies, myoclonic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Apr 2026: Trial registered, NCT07531745
  2. 21 May 2026: Trial started, NCT07531745

The trials

NCT07531745: ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

State
Under way
Phase
Phase 1 and Phase 2
People
32 planned
Started
21 May 2026
Primary completion
Dec 2030
Arms
Part 1: Single Ascending Dose (SAD): Dose Level 1, Part 1: SAD: Dose Level 2, Part 1: SAD: Dose Level 3, Part 1: SAD: Dose Level 4, Part 2: Multiple Ascending Dose (MAD): Dose Level 1-4
Results
None posted
  1. 15 Apr 2026: Trial registered
  2. 21 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.